Boston Therapeutics Enters Into Manufacturing Agreement With Patheon

Boston Therapeutics has entered into an agreement with Patheon to manufacture pharmaceutical grade BTI-320 tablets. BTI-320,  the leading drug candidate for Boston Therapeutics, is a compound designed to reduce the elevation of blood glucose after meals. BTI-320 works by blocking the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars and limit the availability of glucose for absorption into the bloodstream.

Boston Therapeutics signs the agreement along with its strategic partner, Advance Pharmaceutical Company, which is based out of Hong Kong. Boston Therapeutics is expected to begin its IND filing in late 2014, as well as start international Phase III clinical trials for the BTI-320 drug in 2015. It is expected that Patheon, over the course of six months, will manufacture a batch of BTI-320, which will undergo various development, analytical, and stability tests due to IND regulations.

David Platt, PhD and CEO of Boston Therapeutics, released a statement on the company’s new partnership with Patheon. “The manufacturing of pharma-grade BTI-320 tablets is essential to the preparation for our upcoming IND submission and our planned international Phase III trial. We are pleased to have secured the services of Patheon for this important project, a key step in our BTI-320 development efforts and our continued growth as a company,” said Platt.

Boston Therapeutics is a clinical stage developer of innovator compounds, especially those that treat diabetes and other inflammatory diseases relating to complex carbohydrate chemistry.

Patheon is a global leader in providing drug manufacturing and development services to a host of multinational pharmaceutical and biotechnology companies. The company has 9 development facilities in North America and Europe alone.